Cardiomyopathies

0
Pipeline Programs
4
Companies
2
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Zoll
ZollCA - San Jose
1 program
Heart Rate Monitor Enhanced Treatment OptimizationN/A1 trial
Active Trials
NCT04504188RecruitingEst. Dec 2024
Rocket Pharmaceuticals
1 program
PKP2-ACM Natural History StudyN/A1 trial
Active Trials
NCT06644742Recruiting36Est. Apr 2031

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Rocket PharmaceuticalsPKP2-ACM Natural History Study
ZollHeart Rate Monitor Enhanced Treatment Optimization

Clinical Trials (2)

Total enrollment: 36 patients across 2 trials

NCT06644742Rocket PharmaceuticalsPKP2-ACM Natural History Study

PKP2-ACM Natural History Study

Start: Mar 2026Est. completion: Apr 203136 patients
N/ARecruiting
NCT04504188ZollHeart Rate Monitor Enhanced Treatment Optimization

Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator

Start: Mar 2021Est. completion: Dec 2024
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 36 patients
4 companies competing in this space